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Rationale for HDR brachytherapy
The development of the high dose rate (HDR) 192Ir re-
mote afterloader has provided new avenues for perfor-
ming precise genitourinary brachytherapy. A remote
afterloading machine can precisely place a single high
activity 192Ir source (5-10 Curie) into each needle of a ne-
edle array at predetermined points. The source can be
kept at a desired target position along an individual ne-
edle for a specified time period: known as the dwell time.
This imparts a great deal of positive control on the
radiation delivery, while target motion and seed shifting
issues are eliminated. With HDR, highly conformal and
reliable comprehensive radiation coverage is delivered
to the prostate, while undesirable “cold” and “hot” spots
are significantly reduced. The peripheral prostate zones,
where typically bulky portions of tumours reside and
extracapsular tumor penetration occurs, can reliably be
targeted.
Lastly, HDR brachytherapy can provide better spa-
ring of rectum and bladder while delivering a higher dose
to the prostate than even seven-field conformal beam ra-
diotherapy boost [1].
Radiobiology
Emerging radiobiological data from human prostate can-
cer cell lines and from clinical data suggests that prostate
cancer may have an α/β ratio as low as 1.5, much like
a late responding tissue [2, 3]. This is probably due to
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I n t r o d u c t i o n.  The aim of this paper is to describe our experience with high dose rate (HDR) 192Iridium brachytherapy for
prostate cancer and the advantage of this HDR technique.
M e t h o d s  a n d  m a t e r i a l.  Afterloading needles are directly inserted via TRUS guidance into the prostate, transperineally,
using a special template. The dose fractionation scheme is described. HDR brachytherapy as a monotherapy is discussed. 
R e s u l t s.  Outcomes of a series of 104 patients are given, including survival to 10 years where the bNED is 77%.
C o n c l u s i o n s.  HDR brachytherapy has proceeded cautiously since its start-up in the mid-1980s. Now, maturing studies
indicate that multifractionated HDR brachytherapy combined with external beam radiotherapy is a well tolerated and
effective treatment for localised prostate cancer. Early reports also indicate that monotherapy HDR brachytherapy of early
disease is feasible.
Brachyterapia z zastosowaniem wysokiej mocy dawki (irydem 192) w leczeniu raka prostaty 
– doÊwiadczenia grupy z Seattle
W s t ´ p. Celem pracy jest opisanie naszych doÊwiadczeƒ w zakresie brachyterapii wysokà mocà dawki (HDR)
z zastsosowaniem irydu 192 w leczeniu raka prostaty, ze szczególnym uwzgl´dnieniem zalet takiego post´powania.
M a t e r i a ∏  i m e t o d y. Prowadnice do brachyterapii wprowadza sie bezpoÊrednio przez krocze pod kontrolà TRUS,
z zastosowaniem specjalnej p∏ytki. Praca zawiera równie˝ opis metod obliczania dawek promieniowania oraz omówienie
brachyterapii z zastosowaniem wysokiej mocy dawki jako monoterapii.
W y n i k i.  Praca przedstawia wyniki leczenia 104 chorych, wÊród których obserwuje si´ nawet 10-letnie prze˝ycia.
W n i o s k i.  Brachyterapia z zastosowaniem wysokiej mocy dawki rozwija∏a si´ ostro˝nie od czasu swoich poczàtków, to jest od
po∏owy lat osiemdziesiàtych. Obecnie itniejà doniesienia dowodzàce, ˝e brachyterapia wielokrotnie frakcjonowana w po∏àcze-
niu z dawkami promieniowania zewn´trznego, stanowi dobrze tolerowanà i skutecznà metod´ leczenia ograniczonego raka pro-
staty. Ponadto istniejà pierwsze doniesienia sugerujàce, ˝e mo˝liwa jest monoterapia HDR z zastosowaniem izotopów irydu 192.
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the fact that prostate cancer contains a high proportion of
non-proliferating cells.
A tumour with a low α/β ratio such as 1.5 would be
predicted to be a particularly responsive tumour to hypo-
fractionation with larger fraction size as compared to
a conventionally fractionated approach. As such, tumour
cell kill will be relatively higher when fractionated HDR
brachytherapy is employed than with low dose rate treat-
ment (LDR) [4].
In order to keep the potential for adverse late ef-
fects equal, the overall total radiation dose must be lowe-
red when hypofractionated doses are used. Thus there is
a reasonable radiobiological argument for the use of
HDR in the treatment of prostate cancer.
Technique
With the advent of transrectal ultrasound (TRUS), most
institutions performing HDR 192Ir prostate brachythera-
py ultrasonically direct needles transperineally into the
prostate. Various templates to guide needle insertion are
available, examples being the Seattle, Martinez and Syed
templates [5, 6]. Needle counts range from about 12 to 22.
In contradistinction to permanent LDR seed im-
plants, the planning of the radiation delivery is perfor-
med after needle insertion. Institutions use various ima-
ging techniques, such as CT, orthogonal filming or intra-
operative ultrasound for the planning process [5, 6]. The
objective is to identify actual needle locations within the
prostate tissue, the degree of needle deflection, the rela-
tion to known tumour locales and radiation sensitive tis-
sues such as the urethra, bladder, and rectum. This com-
bined information is used to devise an optimal HDR 192Ir
source pattern for the individual patient prior to actual in-
sertion of the 192Ir.
However, the resultant dose distributions from any
of the above techniques are quite similar. Prescribed tar-
get volumes (PTV) are typically 1-3 mm beyond the clini-
cal edge of the prostate, except over the rectum. A mini-
mum peripheral dose (MPD) is prescribed to the PTV.
Doses to the urethra are generally kept to 1.10-1.20 X
MPD and doses of 1.20-1.50 X MPD exist in those re-
gions between the periphery and the urethra [1, 5].
Once a preplan has been approved, the computer-
-controlled HDR afterloading machine precisely places
and moves the 192Ir source within the implanted needle
array according to the plan specifications. Typically, the
prescribed dose, defined by the 100% isodose curve, co-
vers 90% or more of the target volume [1, 5].
Dose Fractionation Schedules
As with every new radiation therapy modality, knowledge
of appropriate dose fraction has evolved with time. Initial
trials investigating the potential usefulness of HDR were
in the form of an HDR boost with external beam to the
prostate, generally in the range of 45-50 Gy.
Early European investigators began with a schedule
of two implants with one HDR fraction rendered per im-
plant. This had the advantage of outpatient treatment,
but necessitated two implants. Doses per HDR fraction
were in the range of 12-15 Gy. Early North American
users were initially more cautious, choosing a single im-
plant with 3-4 HDR fractions rendered per implant, deli-
vering 3.0-4.0 Gy per HDR fraction separated by six hours
or more. This had the advantage of a single implant, but
necessitated that the patient be hospitalised one or two
days to receive the HDR brachytherapy.
Martinez et al have conducted a methodical dose
escalation trial spanning several years [7]. The study vali-
dates that very high dose of HDR brachytherapy dose
can be rendered safe, as long as the total dose is adjusted
accordingly. The American Brachytherapy Society (ABS)
in 1998 convened a consensus panel to draft guidelines for
the use of HDR 192Ir prostate brachytherapy as a boost to
external beam irradiation, Table I.
Outcomes
The first use of HDR 192Ir for prostate brachytherapy
was begun in 1985 at the University of Kiel in Germany by
Bertermann et al [8]. Early reports from this institution
subsequently led others [5, 9, 10] to initiate HDR-IR192
prostate brachytherapy programmes in the late 1980s.
Information regarding long-term efficacy is begin-
ning to emerge as these early feasibility studies mature.
The Kiel group recently reported the eight-year results of
their initial protocol involving 131 patients [11]. A total
of 90 patients had T1-T2 disease, 40 had T3 disease,
and for the entire group the initial mean PSA was
25 ng/ml. With a mean follow-up of eight years, the bio-
chemical no evidence of disease rate (bNED) was 74.8%.
The grade 3 late radiation toxicity, according to the
RTOG/EORTC scoring scheme, was 2.3% for the genito-
urinary and 3.8% for the gastrointestinal system respecti-
vely. No grade 4 or 5 genitourinary/ gastrointestinal mor-
bidity occurred.
Table I. American Brachytherapy Society Consensus Panel: 
example external beam + HDR dose fractionation schedules. EBRT:
external beam radiotherapy. CET: 
California Endocurietherapy Cancer Center, Oakland. LBMMC: 
Long Beach Memorial Medical Center, Long Beach. MMC: 
Memorial Medical Center, New Orleans. SPI: 
Seattle Prostate Institute, Seattle. SC: Scripps Clinic, La Jolla. WBH:
William Beaumont Hospital, Royal Oak
Institution EBRT dose (cGy) HDR fractionation 
(cGy x no. of fractions)
CET 3600 600 x 4 in 2 implants
LBMMC 3960 550-650 x 4 in 1 implant
MMC 4500 550 x 4 in 1 implant
SPI 5040 400 x 4 in 1 implant (1st series)
4500 550 x 3 in 1 implant (2st series)
4500 600 x 3 in 1 implant
SC 5040 550 x 3 in 1 implant
WBH 4600 950 x 2 in 2 implants
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The Seattle group recently reported extended fol-
low-up of its initial group of 104 patients of varying stages
and grades, none of which had hormone therapy [12], Fi-
gure 1. With a mean follow-up of 76 months (median of
75 months and maximum of 124 months) the bNED at fi-
ve years and 10 years was respectively 83% and 77%. Pa-
tients grouped by PSA <10, PSA 10-20, and PSA >20
demonstrated a bNED of 95%, 80% and 42% at 10 years.
Multivariate analysis revealed three independent risk fac-
tors: PSA >15, Gleason score >6, and tumour stage
>T2b. Patients with no risk factors had a bNED of 100%
at five years and 97% at 10 years. Patients with one risk
factor had a bNED of 78% at five years and 69% at 10
years. Patients with 2-3 risk factors showed a bNED of
44% at five years and 33% at 10 years. Long-term toxici-
ty included a 6.7% rate of grade 3 urethral strictures, but
no other significant genitourinary or gastrointestinal mor-
bidity occurred. Changes in the implant technique appe-
ar to have significantly lowered the stricture rate in subse-
quently treated patients.
Several other institutions are reporting five-year out-
comes with similar early results as was seen in the more
mature studies, see Table II. For a group of 136 patients
treated with EBRT and HDR with a mean follow-up of 57
months (range 24-98 months), Quackenbush et al [13]
reported a biochemical control of 92%. No patient rece-
ived androgen suppression. The median PSA nadir was
0.2 ng/ml. According to PSA, the bNED control was
PSA ≤10: 83/86 (97%), PSA >10-20: 32/36 (89%), and
PSA >20: 10/14 (71%). No late Grade 3 or 4 gastrointe-
stinal morbidity was observed. There were six cases (4%)
of Grade 3 genitourinary morbidity, all being bulbar ure-
thral strictures, but no Grade 4 toxicity was observed.
Martinez et al [6] provided an interim report on 142
patients with unfavorable prostate cancer that were pro-
spectively treated in a dose-escalating trial with pelvic
EBRT in combination with HDR, with no androgen sup-
pression. Patient's with any of the following characteristics
were eligible: PSA ≥10.0 ng/ml, Gleason's score ≥7, or
clinical stage T2b or higher. The median follow-up was
2.1 years (range 0.2-7.2 years). Despite the high frequ-
ency of poor prognostic factors, the five-year actuarial
bNED was 63%. The 5-year actuarial rate of RTOG Gra-
de 3 late complications was 9% with no patient experien-
cing Grade 4 or 5 acute or late toxicity.
In most series 2-4% of the patients experienced per-
sistent dysuria or urinary frequency up to one year post-
-treatment [5, 6, 9]. Potency appears to be preserved in
the majority of patients with intact erectile ability before
treatment [5, 6, 9]. However, no prospective quality of
life studies are available for critical review.
Direct comparison with the results achieved with
permanent LDR seed implants is difficult due to different
patient selection criteria and the absence of comparable
outcome data.
Monotherapy
In the above reports, HDR was used as a boost prior to,
during or following external beam. Monotherapy prosta-
te HDR would be attractive for a variety of reasons. The
foremost being the ability to deliver all the treatment
with a highly optimised, conformal and controlled dose
while sparing the adjacent structures due to rapid fall-
-off outside the prostate.
Other reasons include eliminating concerns that or-
gan motion may occur during external beam, and the va-
riable degree of prostate edema that follows seed im-
plants which may affect delivered dose. Furthermore,
there are no radiation safety concerns for the patient and
his immediate family as with permanent LDR seed im-
plants. Lastly, patients would have a significantly shor-
tened course of treatment without the external beam
component.
Early in the history of prostate HDR brachytherapy,
were concerns over potential late effects predicted by the
Figure 1. Seattle Prostate Institute (SPI) results at 10 years. IPSA: ini-
tial PSA. EB: external beam radiotherapy
Table II. PSA control rates with HDR brachytherapy 
and external beam radiotherapy
Reference Number of patients Median PSA Follow-up (months) PSA control (%) End point (ng/ml)
Stromberg [6] 58 14.0 26 85a >1.5 & 2 rises
Eulau [12] 104 12.9 78 77c 3 rises
Galalae [11] 131 25 96 74c 3 rises
Borghede [9] 50 4-10 45 78b >1.0
NR = not reported. a 3-year actuarial. b actual biochemical control during follow-up period. c 10-year actuarial
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prevailing radiobiological theory at the time, and the ab-
sence of any clinical trials prevented any monotherapy
studies. Now, many years later into the HDR prostate
experience, several clinical trials have established the sa-
fety of prostate HDR as a boost. These trials, coupled
with the recent revised thinking over the α/β ratio for
prostate cancer has prompted much interest in using
HDR as a monotherapy treatment.
Several feasible monotherapy studies are now being
reported. The group from Osaka has recently published
preliminary results of a phase I/II clinical trial of HDR in-
terstitial brachytherapy as a monotherapy for localised
prostate cancer [14]. A total of 22 patients with locali-
sed prostate cancer were treated with either 48 Gy in
eight fractions over five days,7/22 cases, or either 54 Gy in
nine fractions over five days, 15/22 cases. During treat-
ment lumbar pain due to prolonged bed rest was the pri-
mary complaint. As scored by RTOG criteria, 11 patients
reported some acute toxicity, but none reported any gra-
de 3 symptoms. With a median follow-up time of 31 mon-
ths and a range of 19-58 months, chronic toxicity appears
quite acceptable. One patient experienced a grade 2 rec-
tal ulcer 22 months post-brachytherapy and another had
occasional grade I rectal bleeding. No significant late ure-
thral or bladder symptoms were reported. PSA response
is satisfactory given the rather advanced stages being tre-
ated.
Martinez et al treated 41 patients with conformal
monotherapy HDR brachytherapy alone with a single
implant of 38 Gy total dose in four fractions of 9.5 Gy
each, delivered twice a day over two days [15]. No patient
experienced any grade 3 or greater acute toxicity.
Similarly, Rodriquez et al at the California Endo-
curietherapy Cancer Center started treating early stage
prostate cancer patients with an HDR monotherapy pro-
tocol in April 1996, with 40 patients treated as of February
2001 (Personal Communication). The fractionation sche-
dule was two implants, one week apart, of three fractions
each. The prescription dose per fraction was either 6.75 or
7.0 Gy, delivered to a 4.5-6.0 mm margin beyond the pro-
static capsule. Of 14 patients with at least a two-year fol-
low-up, no biochemical failures have been observed. Pa-
tients achieved a mean and median PSA of 0.2 ng/ml.
Morbidity was low with no grade 3 or 4 acute or late toxi-
city.
Conclusions
HDR brachytherapy was begun in the mid-1980s and has
proceeded cautiously due to initial concerns over late ef-
fects. Today, maturing studies indicate that multi-fractio-
nated HDR 192Ir brachytherapy combined with moderate
dose external beam radiotherapy is a well tolerated and
effective treatment for localised prostate cancer.
Early reports also indicate that monotherapy HDR
treatment of early prostate cancer is feasible. Though the
adoption of HDR prostate brachytherapy has been slower
than LDR seed implants it is now accelerating. Longer
follow-up and comparative studies are needed to ascerta-
in its position among the various definitive irradiation
schemes for prostate cancer.
Timothy P. Mate
Seattle Prostate Institute
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